Erin Wilson
Stock Analyst at Morgan Stanley
(1.76)
# 3,297
Out of 4,974 analysts
23
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $28 → $22 | $20.32 | +8.27% | 8 | Sep 2, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $139.12 | +426.16% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $163.99 | +134.77% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $187.68 | +41.20% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $486.07 | -57.83% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $174.88 | +42.96% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $18.43 | +106.19% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $21.97 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $492.60 | -30.78% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.58 | +3,317.72% | 4 | Nov 14, 2017 |
Rapid7
Sep 2, 2025
Maintains: Equal-Weight
Price Target: $28 → $22
Current: $20.32
Upside: +8.27%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $139.12
Upside: +426.16%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $163.99
Upside: +134.77%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $187.68
Upside: +41.20%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $486.07
Upside: -57.83%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $174.88
Upside: +42.96%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $18.43
Upside: +106.19%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $21.97
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $492.60
Upside: -30.78%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.58
Upside: +3,317.72%